TARS: Tarsus Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TARS: Tarsus Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,308.21
Enterprise Value ($M) 1,113.08
Book Value ($M) 196.99
Book Value / Share 5.21
Price / Book 6.64
NCAV ($M) 187.63
NCAV / Share 4.97
Price / NCAV 6.97

Profitability (mra)
Return on Invested Capital (ROIC) -0.59
Return on Assets (ROA) -0.64
Return on Equity (ROE) -0.78

Liquidity (mrq)
Quick Ratio 6.85
Current Ratio 6.93

Balance Sheet (mrq) ($M)
Current Assets 256.13
Assets 265.49
Liabilities 68.50
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 17.45
Operating Income -143.16
Net Income -135.89

Cash Flow Statement (mra) ($M)
Cash From Operations -117.49
Cash from Investing 140.60
Cash from Financing 130.18

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Rtw Investments, Lp 9.50 23.71
02-14 13G/A Cormorant Asset Management, LP 6.71 27.93
02-14 13G/A Tang Capital Partners Lp 6.70 10.15
02-13 13G/A Vivo Capital IX, LLC 2.70 -60.44
02-09 13G Morgan Stanley 5.90
02-02 13G/A TimesSquare Capital Management, LLC 0.00 -100.00
02-02 13G/A Cowen Financial Products LLC 5.77 36.63
01-26 13G BlackRock Inc. 7.60 89.60
01-22 13G Paradigm Biocapital Advisors LP 5.80

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 103,740 684,003 15.17
2024-05-02 199,259 129,728 153.60
2024-05-01 162,608 208,299 78.06
2024-04-30 82,647 172,553 47.90
2024-04-29 64,743 114,773 56.41

(click for more detail)

Similar Companies
SWTX – SpringWorks Therapeutics, Inc. SYRE – Spyre Therapeutics, Inc.
SYRS – Syros Pharmaceuticals, Inc. TBIO – Telesis Bio, Inc.
TECH – Bio-Techne Corporation


Financial data and stock pages provided by
Fintel.io